NEW YORK— Shares of Depomed fell more than 5 percent in premarket trading Friday, a day after Dublin- based Horizon Pharma dropped its hostile takeover bid of the rival drugmaker. On Thursday, a judge rejected Horizon's effort to quash Depomed's "poison pill" takeover defense, causing Horizon to abandon its more than bid. Depomed repeatedly rejected Horizon's...» Read More
The "Squawk on the Street" take a close look at the offer from Pilgrim's Pride for Hillshire Brands. Pilgrim's Pride wants Hillshire to drop Pinnacle Foods of which Birds Eye Foods is a brand.
CNBC's David Faber and Jim Cramer discuss the latest M&A action, including Valeant Pharmaceuticals raising its takeover bid for Allergan, and GE improving its offer for France's Alstom.
CNBC's Dominic Chu reports Hillshire Brands has responded to the proposal by Pilgrim's Pride to acquire Hillshire for about $6.4 billion
The "Squawk on the Street" news team discusses the report that Pilgrim's Pride is offering to acquire Hillshire Brands for $6.4 billion.
Don't start your trading day without finding out what CNBC's Jim Cramer is watching ahead of the opening bell. Today Cramer shares his thoughts on Pilgrim Pride's bid for Hillshire Brands.
John Eade, Argus Research, discusses Pfizer's likely next move after abandoning its attempt to buy AstraZeneca. There's a good chance AstraZeneca management could ask Pfizer to come back to the table, says Eade.
$117 billion was not enough for AstraZeneca. CNBC's Meg Tirrell looks at Pfizer and AstraZeneca's stocks.
CNBC's Herb Greenberg plays a game of "deal or no deal" and rounds up potential next takeover targets.
CNBC's David Faber reports Hillshire Brands is buying Pinnacle Foods. And Faber comments on Allergan's rejection of Valeant's takeover bid.
Allergan has rejected a $47 billion takeover bid by Valeant Pharmaceuticals. The "Squawk on the Street" news team discuss m&a in pharmaceuticals and the IPO market.
Bill Ackman, Pershing Square Capital Management, explains what led him to reach out to activist investor Carl Icahn. Ackman calls him "a charming guy."
Bill Ackman, Pershing Square Capital Management, weighs in on the Valeant and Allergan controversy and long-term shareholder activism.
CNBC's Scott Wapner speaks to Bill Ackman, Pershing Square Capital Management, about the "winding down" of the old version of Fannie and Freddie and discusses the importance of reform to their programs.
AstraZeneca has rejected Pfizer's sweetened bid claiming it undervalues the company. The "Squawk on the Street" news team shares their thoughts on the latest bid and the U.S. tax code.
Pfizer CEO Ian Read recently met with U.K.-based investors to discuss a second bid for AstraZeneca, valuing the firm at $106 billion, sources said.
Alstom has until June 2 to review General Electric's $13.5 billion bid for its energy assets, reports CNBC's Mary Thompson.
Alstom is accepting GE's $13.5 billion bid for its energy assets, reports CNBC's Mary Thompson.
Jeffrey Immelt, General Electric chairman & CEO, discusses how the synergies between GE and Alstrom will likely drive earnings and increase the company's industrial mix.
CNBC's Mary Thompson reports the latest details on General Electric's attempt to acquire French company Alstom.
Nicholas Heymann, William Blair analyst, discusses General Electric's attempt to acquire Alstrom but Germany's Siemens AG is not giving up its pursuit either. Currently GE has the green light from Alstrom shareholders, says Heymann.